Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Drospirenone

FDA-approved product (tablet, oral), marketed as Drospirenone, Slynd.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Drospirenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Progestogens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Drospirenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Drospirenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia

    NCT01319500 · start 2009-02

    Registered record
    Registry ID
    NCT01319500
    Conditions
    Contraception
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-02
    Completion
    Not recorded
    Enrolment
    3,776

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • YAZ Premenstrual Dysphoric Disorder (PMDD) in China

    NCT00824187 · start 2009-01

    Registered record
    Registry ID
    NCT00824187
    Conditions
    Premenstrual Dysphoric Disorder ( PMDD)
    Interventions
    EE20/DRSP(YAZ, BAY86-5300); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01
    Completion
    2011-01
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Dysphoric Disorder ( PMDD)
    InterventionEE20/DRSP(YAZ, BAY86-5300); Placebo
    PhasePhase 3
    Registry statusCompleted

  • GA YAZ ACNE in China Phase III

    NCT00818519 · start 2008-12

    Registered record
    Registry ID
    NCT00818519
    Conditions
    Acne Vulgaris
    Interventions
    EE20/Drospirenone (YAZ, BAY86-5300); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-05
    Enrolment
    179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionEE20/Drospirenone (YAZ, BAY86-5300); Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

    NCT00722800 · start 2008-10

    Registered record
    Registry ID
    NCT00722800
    Conditions
    Hidradenitis Suppurativa
    Interventions
    drospirenone and ethinyl estradiol (YAZ); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2011-12
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa
    Interventiondrospirenone and ethinyl estradiol (YAZ); Placebo
    PhasePhase 2
    Registry statusTerminated

  • Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females

    NCT00745901 · start 2008-05

    Registered record
    Registry ID
    NCT00745901
    Conditions
    Contraception
    Interventions
    Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-10
    Enrolment
    355

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionNorgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol
    PhasePhase 4
    Registry statusCompleted

  • Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being

    NCT00988910 · start 2008-01

    Registered record
    Registry ID
    NCT00988910
    Conditions
    Contraception
    Interventions
    EE30-DRSP (Yasmin, BAY86-5131); Other combined oral contraceptives
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-12
    Enrolment
    632

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEE30-DRSP (Yasmin, BAY86-5131); Other combined oral contraceptives
    PhaseNot recorded
    Registry statusCompleted

  • SH T00186 in the Treatment of Primary Dysmenorrhea

    NCT00569244 · start 2007-12

    Registered record
    Registry ID
    NCT00569244
    Conditions
    Primary Dysmenorrhea
    Interventions
    Drug: YAZ flex (SH T00186D); YAZ (SH T00186D)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2009-12
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Dysmenorrhea
    InterventionDrug: YAZ flex (SH T00186D); YAZ (SH T00186D)
    PhasePhase 3
    Registry statusCompleted

  • SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

    NCT00511797 · start 2007-07

    Registered record
    Registry ID
    NCT00511797
    Conditions
    Dysmenorrhea
    Interventions
    SH T04740B; SH T00186DF; SH T04740F; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-01
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDysmenorrhea
    InterventionSH T04740B; SH T00186DF; SH T04740F; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

    NCT00446199 · start 2007-03

    Registered record
    Registry ID
    NCT00446199
    Conditions
    Vasomotor Symptoms; Hot Flashes
    Interventions
    0.5mg DRSP / 0.5mg E2 (BAY86-4891); 0.25mg DRSP / 0.5mg E2 (BAY86-4891); Estradiol (E2 0.3mg); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-11
    Enrolment
    735

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Symptoms; Hot Flashes
    Intervention0.5mg DRSP / 0.5mg E2 (BAY86-4891); 0.25mg DRSP / 0.5mg E2 (BAY86-4891); Estradiol (E2 0.3mg); Placebo
    PhasePhase 3
    Registry statusCompleted

  • PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives

    NCT00948402 · start 2006-12

    Registered record
    Registry ID
    NCT00948402
    Conditions
    Polycystic Ovarian Syndrome; Insulin Sensitivity
    Interventions
    Metformin; oral contraceptive
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12
    Completion
    2009-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovarian Syndrome; Insulin Sensitivity
    InterventionMetformin; oral contraceptive
    PhasePhase 3
    Registry statusCompleted

  • Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)

    NCT01253174 · start 2006-08

    Registered record
    Registry ID
    NCT01253174
    Conditions
    Contraception
    Interventions
    EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131); EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca); L-5-MTHF Ca 0.451 mg (Metafolin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131); EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca); L-5-MTHF Ca 0.451 mg (Metafolin)
    PhasePhase 1
    Registry statusCompleted

  • Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

    NCT01182207 · start 2006-07

    Registered record
    Registry ID
    NCT01182207
    Conditions
    Healthy
    Interventions
    Drospirenone/Ethinyl Estradiol (Gianvi®); YAZ®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-08
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDrospirenone/Ethinyl Estradiol (Gianvi®); YAZ®
    PhasePhase 1
    Registry statusCompleted

  • Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

    NCT01182194 · start 2006-06

    Registered record
    Registry ID
    NCT01182194
    Conditions
    Healthy
    Interventions
    Drospirenone/Ethinyl Estradiol (Gianvi®); YAZ®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-06
    Completion
    2006-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDrospirenone/Ethinyl Estradiol (Gianvi®); YAZ®
    PhasePhase 1
    Registry statusCompleted

  • Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

    NCT00640224 · start 2005-03

    Registered record
    Registry ID
    NCT00640224
    Conditions
    Polycystic Ovary Syndrome
    Interventions
    rosiglitazone; drospirenone/ethinyl estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-03
    Completion
    2015-07
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome
    Interventionrosiglitazone; drospirenone/ethinyl estradiol
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

    NCT00651599 · start 2004-07

    Registered record
    Registry ID
    NCT00651599
    Conditions
    Vasomotor Symptoms
    Interventions
    Angeliq (Drospirenone/17ß-estradiol, BAY86-4891); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Symptoms
    InterventionAngeliq (Drospirenone/17ß-estradiol, BAY86-4891); Placebo
    PhasePhase 3
    Registry statusCompleted